SEARCH

SEARCH BY CITATION

References

  • 1
    Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr 2007; 86: 285-300.
  • 2
    Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008; 48: 993-999.
  • 3
    Carpentier A, Taghibiglou C, Leung N, Szeto L, Van Iderstine SC, Uffelman KD, et al. Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster. J Biol Chem 2002; 277: 28795-28802.
  • 4
    Taghibiglou C, Carpentier A, Van Iderstine SC, Chen B, Rudy D, Aiton A, et al. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance: evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem 2000; 275: 8416-8425.
  • 5
    Roglans N, Vilà L, Farré M, Alegret M, Sánchez RM, Vázquez-Carrera M, et al. Impairment of hepatic STAT3 activation and reduction of PPAR alpha activity in fructose-fed rats. HEPATOLOGY 2007; 45: 778-788.
  • 6
    Vilà L, Roglans N, Alegret M, Sànchez RM, Vàzquez-Carrera M, Laguna JC. Suppressor of cytokine signaling-3 (SOCS3) and a deficit of serine/threonine (Ser/Thr) phosphoproteins involved in leptin transduction mediate the effect of fructose on rat liver lipid metabolism. HEPATOLOGY 2008; 48: 1506-1516.
  • 7
    Kelley GL, Allan G, Azhar S. High dietary fructose induces a hepatic stress response resulting in cholesterol and lipid dysregulation. Endocrinology 2004; 145: 548-555.
  • 8
    Li P, Koike T, Qin B, Kubota M, Kawata Y, Jia YJ, et al. A high-fructose diet impairs Akt and PKCzeta phosphorylation and GLUT4 translocation in rat skeletal muscle. Horm Metab Res 2008; 40: 528-532.
  • 9
    Shapiro A, Mu W, Roncal C, Cheng KY, Johnson RJ, Scarpace PJ. Fructose-induced leptin resistance exacerbates weight gain in response to subsequent high-fat feeding. Am J Physiol Regul Integr Comp Physiol 2008; 295: R 1370-1375.
  • 10
    Lee Y, Yu X, Gonzales F, Mangelsdorf DJ, Wang MY, Richardson C, et al. PPAR alpha is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue. Proc Natl Acad Sci U S A 2002; 99: 11848-11853.
  • 11
    Goldstein BJ, Bittner-Kowalczyk A, White MF, Harbeck M. Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B: possible facilitation by the formation of a ternary complex with the GRB2 adaptor protein. J Biol Chem 2000; 275: 4283-4289.
  • 12
    Wang N, Zhang D, Mao X, Zou F, Jin H, Ouyang J. Astragalus polysaccharides decreased the expression of PTP1B through relieving ER stress induced activation of ATF6 in a rat model of type 2 diabetes. Mol Cell Endocrinol 2009; 307: 89-98.
  • 13
    Zinker BA, Rondinone CM, Trevillyan JM, Gum RJ, Clampit JE, Waring JF, et al. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci U S A 2002; 99: 11357-11362.
  • 14
    Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A, Haj F, Wang Y, Minokoshi Y, et al. PTP1B regulates leptin signal transduction in vivo. Dev Cell 2002; 2: 489-495.
  • 15
    Bence KK, Delibegovic M, Xue B, Gorgun CZ, Hotamisligil GS, Neel BG, et al. Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat Med 2006; 12: 917-924.
  • 16
    Taghibiglou C, Rashid-Kolvear F, Van Iderstine SC, Le-Tien H, Fantus IG, Lewis GF, et al. Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance. J Biol Chem 2002; 277: 793-803.
  • 17
    Shimizu S, Ugi S, Maegawa H, Egawa K, Nishio Y, Yoshizaki T, et al. Protein-tyrosine phosphatase 1B as new activator for hepatic lipogenesis via sterol regulatory element-binding protein-1 gene expression. J Biol Chem 2003; 278: 43095-43101.
  • 18
    Shapiro H, Bruck R. Therapeutic potential of curcumin in non-alcoholic steatohepatitis. Nutr Res Rev 2005; 18: 212-221.
  • 19
    Leclercq IA, Farrell GC, Sempoux C, dela Peña A, Horsmans Y. Curcumin inhibits NF-kappa B activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol 2004; 41: 926-934.
  • 20
    Jang EM, Choi MS, Jung UJ, Kim MJ, Kim HJ, Jeon SM, et al. Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamsters. Metabolism 2008; 57: 1576-1583.
  • 21
    Tang Y, Zheng S, Chen A. Curcumin eliminates leptin's effects on hepatic stellate cell activation via interrupting leptin signaling. Endocrinology 2009; 150: 3011-3020.
  • 22
    Dean D, Fan J, Whitehouse D, Balkan B. Time and tissue specific insulin sensitization in response to a PPAR-alpha agonist, a PPAR-gamma agonist, and a PTP-1b inhibitor in high fat fed rats after 1 and 10 day treatments. Diabetes 2005; 54: A152-153.
  • 23
    Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-2307.
  • 24
    Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-917.
  • 25
    Banks AS, Davis SM, Bates SH, Myers MG Jr. Activation of downstream signals by the long form of the leptin receptor. J Biol Chem 2000; 275: 14563-14572.
  • 26
    Pari L, Murugan P. Antihyperlipidemic effect of curcumin and tetrahydrocurcumin in experimental type 2 diabetic rats. Ren Fail 2007; 29: 881-889.
  • 27
    Sparks JD, Sparks CE. Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim Biophys Acta 1994; 1215: 9-32.
  • 28
    Guerre-Millo M, Gervois P, Raspé E, Madsen L, Poulain P, Derudas B, et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 2000; 275: 16638-16642.
  • 29
    Wang R, Li YH, Xu Y, Li YB, Wu HL, Guo H, et al. Curcumin produces neuroprotective effects via activating brain-derived neurotrophic factor/TrkB-dependent MAPK and PI-3K cascades in rodent cortical neurons. Prog Neuropsychopharmacol Biol Psychiatry 2009; doi:10.1016/j.pnpbp.2009.10.016.
  • 30
    Münzberg H, Björnholm M, Bates SH, Myers MG Jr. Leptin receptor action and mechanisms of leptin resistance. Cell Mol Life Sci 2005; 62: 642-652.
  • 31
    Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 2004; 24: 5434-5446.
  • 32
    Rezende LF, Vieira AS, Negro A, Langone F, Boschero AC. Ciliary neurotrophic factor (CNTF) signals through STAT3-SOCS3 pathway and protects rat pancreatic islets from cytokine-induced apoptosis. Cytokine 2009; 46: 65-71.
  • 33
    Egawa K, Maegawa H, Shimizu S, Morino K, Nishio Y, Bryer-Ash M, et al. Protein-tyrosine phosphatase-1B negatively regulates insulin signaling in 16 myocytes and Fao hepatoma cells. J Biol Chem 2001; 276: 10207-10211.
  • 34
    Blanquart C, Karouri SE, Issad T. Implication of protein tyrosine phosphatase 1B in MCF-7 cell proliferation and resistance to 4-OH tamoxifen. Biochem Biophys Res Commun 2009; 387: 748-753.
  • 35
    Zinker BA, Rondinone CM, Trevillyan JM, Gum RJ, Clampit JE, Waring JF, et al. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci U S A 2002; 99: 11357-11362.
  • 36
    Waring JF, Ciurlionis R, Clampit JE, Morgan S, Gum RJ, Jolly RA, et al. PTP1B antisense-treated mice show regulation of genes involved in lipogenesis in liver and fat. Mol Cell Endocrinol 2003; 203: 155-168.
  • 37
    Zhang ZY, Lee SY. PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity. Expert Opin Investig Drugs 2003; 12: 223-233.
  • 38
    Morrison CD, White CL, Wang Z, Lee SY, Lawrence DS, Cefalu WT, et al. Increased hypothalamic protein tyrosine phosphatase 1B contributes to leptin resistance with age. Endocrinology 2007; 148: 433-440.
  • 39
    Cheong SH, Cho H, Chang KJ. Effect of PTP1B inhibitors and taurine on blood lipid profiles in adolescent obesity. Adv Exp Med Biol 2009; 643: 381-388.